Suppression of Drug Resistance in Dengue Virus
ABSTRACT Dengue virus is a major human pathogen responsible for 400 million infections yearly. As with other RNA viruses, daunting challenges to antiviral design exist due to the high error rates of RNA-dependent RNA synthesis. Indeed, treatment of dengue virus infection with a nucleoside analog res...
Saved in:
Main Authors: | Roberto Mateo, Claude M. Nagamine, Karla Kirkegaard |
---|---|
Format: | article |
Language: | EN |
Published: |
American Society for Microbiology
2015
|
Subjects: | |
Online Access: | https://doaj.org/article/fca0a1a02dcf4272b992bde8f4d1ca32 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Targeted Computational Screen of the SWEETLEAD Database Reveals FDA-Approved Compounds with Anti-Dengue Viral Activity
by: Jasmine Moshiri, et al.
Published: (2020) -
Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus
by: J. A. Swanstrom, et al.
Published: (2016) -
Dengue Virus Genome Uncoating Requires Ubiquitination
by: Laura A. Byk, et al.
Published: (2016) -
Role of Complement in Dengue Virus Infection: Protection or Pathogenesis?
by: Sujan Shresta
Published: (2012) -
Complement-Mediated Neutralization of Dengue Virus Requires Mannose-Binding Lectin
by: Panisadee Avirutnan, et al.
Published: (2011)